{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:24:38Z","timestamp":1792819478134,"version":"4.5.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,6,15]]},"DOI":"10.1001\/jama.2021.7665","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T15:01:12Z","timestamp":1623769272000},"page":"2348","source":"Crossref","is-referenced-by-count":93,"title":["Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack"],"prefix":"10.1001","volume":"325","author":[{"given":"Paul K.","family":"Winner","sequence":"first","affiliation":[{"name":"Palm Beach Headache Center, West Palm Beach, Florida"},{"name":"Neurology Research Institute Palm Beach, West Palm Beach, Florida"},{"name":"Premiere Research Institute, West Palm Beach, Florida"},{"name":"Palm Beach Neurology, West Palm Beach, Florida"},{"name":"Nova Southeastern University, Fort Lauderdale, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[{"name":"New England Institute for Neurology and Headache, Stamford, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chakhava","sequence":"additional","affiliation":[{"name":"D. Tvildiani Medical University, Multiprofile Clinic Consilium Medulla, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Krog Josiassen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Lindsten","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahar","family":"Mehta","sequence":"additional","affiliation":[{"name":"Lundbeck Seattle BioPharmaceuticals Inc, Bothell, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[{"name":"Lundbeck La Jolla Research Center, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi210054r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition.","volume":"38","author":"Headache Classification Committee of the International Headache Society","year":"2018","journal-title":"Cephalalgia"},{"issue":"7","key":"joi210054r2","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/head.v60.7","article-title":"A real-world analysis of patient characteristics, treatment patterns, and level of impairment in patients with migraine who are insufficient responders vs responders to acute treatment.","volume":"60","author":"Lombard","year":"2020","journal-title":"Headache"},{"issue":"3","key":"joi210054r3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.2019.59.issue-3","article-title":"Migraine progression: a systematic review.","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"issue":"1","key":"joi210054r4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10194-020-01111-8","article-title":"From transformation to chronification of migraine: pathophysiological and clinical aspects.","volume":"21","author":"Torres-Ferr\u00fas","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"joi210054r5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","article-title":"Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide.","volume":"374","author":"Garcia-Martinez","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"joi210054r7","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.567","article-title":"Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine.","volume":"8","author":"Baker","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"10","key":"joi210054r8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.v60.10","article-title":"Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing.","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"issue":"9","key":"joi210054r9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial.","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"issue":"3","key":"joi210054r10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1).","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"issue":"13","key":"joi210054r11","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"joi210054r12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-020-01186-3","article-title":"Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24?weeks of treatment in the phase 3 PROMISE-2 (Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2) study.","volume":"21","author":"Silberstein","year":"2020","journal-title":"J Headache Pain"},{"issue":"12","key":"joi210054r13","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","article-title":"Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study.","volume":"42","author":"Smith","year":"2020","journal-title":"Clin Ther"},{"issue":"1","key":"joi210054r14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice.","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"issue":"9","key":"joi210054r15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/ene.2009.16.issue-9","article-title":"EFNS guideline on the drug treatment of migraine\u2014revised report of an EFNS task force.","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"issue":"3","key":"joi210054r16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","article-title":"A practical guide to understanding Kaplan-Meier curves.","volume":"143","author":"Rich","year":"2010","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"joi210054r17","first-page":"973","article-title":"Preventive migraine treatment.","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"issue":"19","key":"joi210054r18","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine.","volume":"383","author":"Ashina","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"joi210054r19","first-page":"S1","article-title":"Canadian Headache Society guideline for migraine prophylaxis.","volume":"39","author":"Pringsheim","year":"2012","journal-title":"Can J Neurol Sci"},{"issue":"6","key":"joi210054r21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","article-title":"Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition.","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"key":"joi210054r6","year":"2020"},{"key":"joi210054r20","unstructured":"US Food and Drug Administration. Migraine: Developing Drugs for Acute Treatment: Guidance for Industry. Published February 2018. Accessed September 3, 2019. https:\/\/www.fda.gov\/media\/89829\/download"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2781053\/jama_winner_2021_oi_210054_1623359389.52675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T22:34:30Z","timestamp":1699137270000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2781053"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":21,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.7665","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}